

Foreword


Dear Ladies and Gentlemen,
We would like to invite you to our **3rd UROART Symposium on January 17, 2025** at the University Hospital, Basel.

Are you curious about the latest advancements for your bladder cancer patients?

Then don't miss the 3rd UROART Symposium, taking place in Basel on Friday, January 17, 2025!

The event will feature live robotic surgeries, including cystectomy and intracorporeal urinary diversion, performed by the renowned Prof. Wiklund and Dr. Hosseini. The morning will be dedicated to non-muscle-invasive disease, followed by a keynote lecture by Prof. Peter Black on emerging biomarkers essential for guiding treatment decisions. In the afternoon, we will shift the focus to muscle-invasive disease with discussions on promising bladder-preserving strategies, involving collaboration among urologists, oncologists, and radiation oncologists.

We look forward to welcoming you in Basel,


Helge Seifert, MD
Head of Urology


Richard Cathomas, MD
Scientific Board


Cyrill A. Rentsch, MD, PhD
Scientific Board


Thomas J. Lautenschlager
Senior Healthcare Expert

Information & Registration

Event date:

Friday, January 17, 2025

Credits:

6 SGU

Participation fee online registration:

CHF 135.- incl. breaks and standing lunch

CHF 85.- for residents and researchers

Participation fee fax or mail registration:

CHF 140.- incl. breaks and standing lunch

Contact for event registration:

anmeldung@med-management.ch

Postal address:

UROART
c/o LH Medical Management GmbH
Postfach 96
6000 Luzern 6

Registration deadline:

January 16, 2025 (box office thereafter)

Venue:

ZLF-Hörsaal
Hebelstrasse 20
4031 Basel

Contact responsible for the event:

Miriam Stabile
Tel.: +41 61 921 74 74

info@med-management.ch

www.uro-art.ch

More information and

registration at:

www.uro-art.ch

We would like to thank all the companies that have supported us in recent years!

Main sponsor

Johnson & Johnson

Sponsor

abbvie

accord
We make it better

ANKLIN
Excellence in Endoscopic Solutions

astellas
Leading Light for Life

BAYER
Bayer

Debiopharm Group
WE DEVELOP FOR PATIENTS

ORION
PHARMA

MSD

FARCO MELISANA

UROART
BASEL



3. UROART Symposium

Treatment Revolutions in Bladder Cancer

January 17, 2025

University Hospital Basel, Department of Urology

www.uro-art.ch

Program

8:30 Registration & Welcome coffee

9:00 Welcome speech
Helge Seifert, MD, University Hospital Basel, Switzerland

09:05 «Live Surgery»
Peter Wiklund, MD, Karolinska Institute, Stockholm, Sweden
Hosseini Aliabad Seyed Abolfazl, MD, University Hospital Basel, Switzerland

Chair: *Karen Fransis, MD, PhD, University Hospital Antwerp, Edegem, Belgium*
Ashkan Mortezaei, MD, University Hospital Zurich, Switzerland

09:10 Introduction – NMIBC
Cyrill A. Rentsch, MD, PhD, University Hospital Basel, Switzerland

Chair: *Ilaria Lucca, MD, CHUV, Lausanne, Switzerland*
Cédric Poyet, MD, City Hospital Triemli, Zurich, Switzerland

09:15 The potential for urinary markers to replace cystoscopy
Lukas Bubendorf, MD, Prof, University Hospital Basel, Basel, Switzerland

10:10 «Live Surgery»

10:15 The future of BCG-naive NMIBC therapy
Paolo Gontero, MD, Ospedale Molinette, Turin, Italy

10:40 «Live Surgery»

10:45 Coffee break (*industrial exhibition*)

11:15 «Live Surgery»

11:20 BCG unresponsive: Upcoming perspectives for the unfit or unwilling and beyond
Piyush K. Agarwal, MD, Comprehensive Cancer Research Center, The University of Chicago, USA

11:45 **Keynote lecture:**
Biomarkers guiding the future treatment of localized bladder cancer
Peter Black, MD, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada

Chair: *Helge Seifert, MD, University Hospital Basel, Switzerland*

12:30 «Live Surgery»

12:35 Lunch (*industrial exhibition*)

13:30 «Live Surgery»

13:35 Introduction – MIBC Muscle invasive bladder cancer
Richard Cathomas, MD, Cantonal Hospital Graubünden, Chur, Switzerland

Chair: *Roland Seiler, MD, Cantonal Hospital Biel, Switzerland*
Massimo Valerio, MD, HUG, Geneva, Switzerland

13:40 From neoadjuvant to perioperative and beyond: Systemic therapy as a cornerstone
Stefanie Fischer, MD, Cantonal Hospital St. Gallen, Switzerland

14:05 «Live Surgery»

14:10 Bladder-sparing with TMT: The present and future
Ananya Choudhury, MD, The Christie NHS Foundation Trust, Manchester, Great Britain

14:35 «Live Surgery»

14:40 Coffee break (*industrial exhibition*)

15:10 Tailored treatment approaches for metastatic bladder cancer
Yohann Lorient, MD, PhD, Gustave Roussy Cancer Institute, Villejuif, France

15:45 Panel discussion
Cyrill A. Rentsch, MD, PhD, University Hospital Basel, Switzerland
Richard Cathomas, MD, Cantonal Hospital Graubünden, Chur, Switzerland

16:10 Closing remarks
Helge Seifert, MD, University Hospital Basel, Switzerland

16:15 Networking & Apéro riche (*industrial exhibition*)

**PUSH BACK EARLY.
EXTEND LIFE.¹**

ERLEADA®:
**FOR ALL mHSPC^{1,a,b}
& nmCRPC^{2,c} PATIENTS**

NEW FORMULATION



1. Chi KN et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. *J Clin Oncol.* 2021 Jul 10; 39(20):2294–2303. **2.** Smith MR et al. Apalutamide and Overall Survival in Prostate Cancer. *Eur Urol.* 2021 Jan; 79(1):150–158. DOI: 10.1016/j.eururo.2020.08.011. Epub 2020 Sep 6. **3.** ERLEADA® Information for Healthcare Professionals (Mai 2024), www.swissmedinfo.ch.

^aUnder ADT; TITAN study: HR = 0.65; 95% CI: 0.53–0.79; p < 0.0001. ^bRegardless of extent or risk of disease (high-/low-volume, Gleason score, newly/previously diagnosed) or prior therapy (docetaxel, ADT, local therapies). ^cUnder ADT, with PSA doubling time ≤ 10 months and without distant metastases.

References upon request by Janssen-Cilag AG.

Erleada® apalutamid 60 mg or 240 mg film-coated tablets. **I:** In combination with androgen deprivation therapy (ADT) for adults with either non-metastatic, castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastasis, particularly where PSADT ≤ 10 months, or metastatic, hormone-sensitive prostate cancer (mHSPC). **D:** 240 mg (4 x 60 mg tablets or 1 x 240 mg tablet), administered orally, once daily; note dosage modifications. **Ci:** Hypersensitivity to the active substance or to one of the excipients depending on the composition, and women with no indication or who are pregnant or of childbearing potential. **WP:** caution in patients at risk or with a history of ischaemic heart disease, recent cardiovascular disease, seizures, falls, fractures, QT prolongation, and severe cutaneous adverse reactions; men and women should use effective contraception (as fetal development abnormalities may occur). **AR:** Very common (≥ 1/10): arthralgia, diarrhoea, fatigue, fractures, weight loss, skin rash, flushing, hypertension, falls and decreased appetite. **Common** (≥ 1/100 to < 1/10): Alopecia, dysgeusia, hypercholesterolaemia, hypertriglyceridaemia, hypothyroidism, ischaemic heart disease, ischaemic cerebrovascular disorders, muscle spasms and pruritus. **DI:** Medicinal products that prolong the QT interval, CYP3A4 and CYP2C8 inhibitors or inducers and substrates of BCRP, CYP3A4, CYP2B6, CYP2C8/9/19, OAT3, OATP1B1, P-gp and UGT. **Packaging:** blister pack containing 112 film-coated tablets (60 mg, 4 x 28) or 28 film-coated tablets (240 mg, 2 x 14). **Prescribing category:** B; detailed information: www.swissmedinfo.ch. **Marketing authorisation holder:** Janssen-Cilag AG, Gubelstrasse 34, 6300 Zug, (CH_CP-327595)

©Janssen-Cilag AG, a Johnson & Johnson company
Gubelstrasse 34, CH-6300 Zug

CH_CP-379439_02_2024